- 专利标题： SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4
-
申请号： US17263071申请日： 2019-07-26
-
公开(公告)号： US20220089609A1公开(公告)日： 2022-03-24
- 发明人: Camille AMALRIC , Anaïs BARRE , Stephan SCHANN , Stanislas MAYER , Ismet DORANGE , Baptiste MANTEAU , Anne-Laure BLAYO
- 申请人： DOMAIN THERAPEUTICS
- 申请人地址： FR IIIkirch-Graffenstaden
- 专利权人： DOMAIN THERAPEUTICS
- 当前专利权人： DOMAIN THERAPEUTICS
- 当前专利权人地址： FR IIIkirch-Graffenstaden
- 优先权： EP18315019.2 20180726
- 国际申请： PCT/EP2019/070178 WO 20190726
- 主分类号： C07D498/10
- IPC分类号： C07D498/10 ; C07D487/04 ; C07D401/14 ; C07D495/04 ; C07D413/14 ; C07D405/14 ; C07D519/00 ; A61P25/16
摘要：
The present invention relates to novel quinazolinone derivatives of formula (I) as well as pharmaceutical compositions containing these compounds. The compounds of formula (I) as provided herein can act as positive allosteric modulators of metabotropic glutamate receptor subtype 4 (mGluR4), and can thus be used as therapeutic agents, particularly in the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions or conditions which can be affected by alteration of glutamate level or signalling.
信息查询
